Insulin glargin
| |
| Klinički podaci | |
|---|---|
| Robne marke | Lantus, Lantus OptiSet, Lantus SoloStar |
| AHFS/Drugs.com | glargine.html Monografija |
| Identifikatori | |
| CAS broj | 160337-95-1 |
| ATC kod | A10AE04 |
| DrugBank | DB00047 |
| Hemijski podaci | |
| Formula | C267H404N72O78S6 |
| Fizički podaci | |
| Tačka topljenja | 81 °C (178 °F) |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 30 h |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Insulin glargin je rekombinantni analog ljudskog insulina proizveden pomoću specializovane laboratorijske vrste bakterija Escherichia coli (K12). On je analog ljudskog insulina u kome je asparagine u poziciji A21 zamenjen glicinom i dodata su dva arginina na C-terminusu (u pozicijama B31 i 32) B-lanca. Rezultirajući protein je rastvoran na pH 4 i formira mikroprecipitate na fiziološkom pH 7.4. Male količine insulin glargina se sporo oslovađaju iz mikroprecipitata što daje leku dugo vreme dejstva (do 24 sata) i odsustvo izraženog pika koncentracije.[1][2][3][4][5][6][7][8][9]
- ↑ Chatterjee S, Tringham JR, Davies MJ: Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jul;7(10):1357-71. PMID 16805721
- ↑ Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743-78. PMID 12904090
- ↑ Home PD, Ashwell SG: An overview of insulin glargine. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. PMID 12324987
- ↑ Jones R: Insulin glargine (Aventis Pharma). IDrugs. 2000 Sep;3(9):1081-7. PMID 16049868
- ↑ Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. PMID 12860485
- ↑ Warren E, Weatherley-Jones E, Chilcott J, Beverley C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004 Nov;8(45):iii, 1-57. PMID 15525480
- ↑ Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023. PMID 18715209
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
